Administrative Core

项目总结-行政核心

PROJECT SUMMARY – Administrative Core This Duke/UT Southwestern Glioblastoma Therapeutics Network (GTN) team will complete pre-clinical development of a novel treatment for patients with glioblastoma (GBM) and investigate the biologic activity of this agent in an early-phase clinical trial. In support of this goal, this Administrative Core is responsible for overseeing, integrating, coordinating, and supporting Projects 1 and 2 and the shared Biomarker, Bioinformatics and Biorepository Core. The Administrative Core will oversee the organizational infrastructure, integration of all components, and carry out day-to-day administrative activities; serve as the liaison with all internal and external constituencies; provide support for preparation of reports, manuscripts, and regulatory documents; and foster team science by facilitating collaboration and smooth communication through regular meetings, seminars, and other interactions. It will also provide fiscal management to ensure timely financial accounting and reporting according to university and NIH policies; provide regulatory support to ensure compliance with institutional, state, and federal research guidelines; oversee data operations to ensure use of best practices for data provenance and integrity (e.g., monitoring standards such as SOPs, GCP); provide scientific management by monitoring research progress/productivity and enable effective use of shared resource cores relative to scientific milestones and budget milestones; conduct ongoing rigorous Program evaluations, with guidance and direction provided by a Steering Committee and an Internal Advisory Board; resolve conflict; and delineate specific publication and data distribution policies. Critically, this Core will also oversee interactions with other funded GTN U19 sites, communication with Network Coordination Center, and the use of yearly trans-U19 Pilot Project Funds. This Core is structured to reduce administrative burden, allowing investigators to focus on developing a novel approach for treating adult GBM using an innovative telomerase-mediated telomere-targeting drug, 6-thio-2′- deoxyguanosine (6-thio-dG), through high-quality, rigorous, and efficient research.